Other substances

Conivaptan HCl

A vasopressin receptor antagonist.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Conivaptan hydrochloride is a vasopressin receptor V1a and V2 antagonist. It is used for the treatment of hyponatraemia resulting from the syndrome of inappropriate antidiuretic hormone (ChEBI).

Conivaptan on DrugBank
Conivaptan hydrochloride on PubChem
Conivaptan on Wikipedia

Marketed as

VAPRISOL

 

Structure image - Conivaptan HCl

CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6.Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Small molecule In vitro Screening 		Vero cells 5.09 Nov/25/2020
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
in silico 3.31

In silico screening of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.

 Aug/05/2020
Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2
Spike protein nsp9 Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 Nsp9 replicase.

 Aug/24/2020
Export (.csv)